Further Analysis of a VLS Modified IL-2 Receptor Targeted Toxin
VLS 修饰的 IL-2 受体靶向毒素的进一步分析
基本信息
- 批准号:7480070
- 负责人:
- 金额:$ 14.75万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2008
- 资助国家:美国
- 起止时间:2008-09-01 至 2010-02-28
- 项目状态:已结题
- 来源:
- 关键词:Acute Graft Versus Host DiseaseAdverse effectsAmino Acid SequenceAnimal ModelBiological AssayBiological ModelsBlood CirculationBlood VesselsBrainCellsChimeric ProteinsClassCutaneousDAB389 Interleukin-2 ImmunotoxinDenileukin DiftitoxDevelopmentDiphtheria ToxinDiseaseEndothelial CellsExtravasationFacility Construction Funding CategoryFundingFusion ToxinGoalsHumanIn VitroInterleukin 2 ReceptorLifeLiquid substanceLungMediatingModelingMusMuscleOrganPatientsPermeabilityPharmaceutical PreparationsPhasePopulationProteinsPsoriasisPublic HealthRangeRecombinant Fusion ProteinsRecurrenceRheumatoid ArthritisSalesSeriesSyndromeT-Cell LymphomaTargeted ToxinsTestingTherapeuticTherapeutic AgentsTherapeutic IndexTissuesToxinUnited States Food and Drug AdministrationVascular Endothelial Cellbasecytokine therapycytotoxicityexperiencein vitro Modelin vivoin vivo Modelinterleukin 2-diphtheria toxinmonolayermutantnext generationtool
项目摘要
DESCRIPTION (provided by applicant): The project seeks to further the development of a series of diphtheria toxin mutants which, when employed in the construction of protein fusion toxins, display reduced induction of leakage through vascular endothelial cell monolayers. The goals of this Phase I proposal are to evaluate two, in vivo models of vascular leakage, selecting one model for further in vivo analysis of diphtheria toxin mutants generated by AGI. Successful completion of these studies will result in the determination of modified diphtheria toxin toxophores suitable for protein fusion toxin development and testing in disease-specific, in vivo models. Vascular leakage in humans is a common side effect of fusion toxin therapy and may be inhibiting the development of this class of therapeutic agent. Advances in reduction of vascular leakage could enhance the therapeutic index of these drugs and make them available to a wider population of patients. Currently there is only one FDA approved drug in this class, ONTAK, which is used to treat persistent or recurrent cutaneous T-cell lymphoma. Sales of this drug range between $30 and $40M annually. PUBLIC HEALTH RELEVANCE: This project seeks to develop modified diphtheria toxin interleukin-2 molecules with reduced side effect profiles. In excess of 30% of all patients that currently receive DAB389IL-2, or ONTAK(r), experience vascular leak syndrome. The molecules being developed and tested in these studies will potentially provide a path for the development of the next generation of ONTAK(r) that may be more appropriate for a wider patient population afflicted with a broader range of diseases.
描述(由申请人提供):该项目旨在进一步开发一系列白喉毒素突变体,当用于构建蛋白融合毒素时,其显示通过血管内皮细胞单层的渗漏诱导减少。本I期提案的目标是评估两种血管渗漏的体内模型,选择一种模型用于进一步体内分析由AGI产生的白喉毒素突变体。这些研究的成功完成将导致适合于蛋白融合毒素开发和疾病特异性体内模型测试的修饰白喉毒素毒基的确定。人体血管渗漏是融合毒素治疗的常见副作用,可能会抑制这类治疗药物的发展。减少血管渗漏的进展可以提高这些药物的治疗指数,使其可用于更广泛的患者人群。目前只有一种FDA批准的药物,ONTAK,用于治疗持续性或复发性皮肤T细胞淋巴瘤。这种药物的销售额每年在3000万至4000万美元之间。公共卫生相关性:该项目旨在开发具有减少副作用的修饰白喉毒素白细胞介素-2分子。目前接受DAB 389 IL-2或ONTAK(r)治疗的所有患者中,超过30%的患者出现血管渗漏综合征。在这些研究中开发和测试的分子将可能为开发下一代ONTAK(r)提供一条途径,这可能更适合于患有更广泛疾病的更广泛患者人群。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
JOHANNA Catharina VANDERSPEK其他文献
JOHANNA Catharina VANDERSPEK的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('JOHANNA Catharina VANDERSPEK', 18)}}的其他基金
Generation of a Modified DT_IL3 Fusion Toxin
改良 DT_IL3 融合毒素的生成
- 批准号:
7483540 - 财政年份:2008
- 资助金额:
$ 14.75万 - 项目类别:
Modified Diphtheria Toxin IL-7 Fusion Toxins
改良白喉毒素 IL-7 融合毒素
- 批准号:
7110847 - 财政年份:2006
- 资助金额:
$ 14.75万 - 项目类别:
An IL-2 Receptor Targeted Toxin with Reduced VLS
具有减少 VLS 的 IL-2 受体靶向毒素
- 批准号:
6883320 - 财政年份:2005
- 资助金额:
$ 14.75万 - 项目类别:
相似海外基金
Unraveling Adverse Effects of Checkpoint Inhibitors Using iPSC-derived Cardiac Organoids
使用 iPSC 衍生的心脏类器官揭示检查点抑制剂的副作用
- 批准号:
10591918 - 财政年份:2023
- 资助金额:
$ 14.75万 - 项目类别:
Optimization of mRNA-LNP vaccine for attenuating adverse effects and analysis of mechanism behind adverse effects
mRNA-LNP疫苗减轻不良反应的优化及不良反应机制分析
- 批准号:
23K15383 - 财政年份:2023
- 资助金额:
$ 14.75万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Elucidation of adverse effects of combined exposure to low-dose chemicals in the living environment on allergic diseases and attempts to reduce allergy
阐明生活环境中低剂量化学品联合暴露对过敏性疾病的不良影响并尝试减少过敏
- 批准号:
23H03556 - 财政年份:2023
- 资助金额:
$ 14.75万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Green tea-based nano-enhancer as an adjuvant for amplified efficacy and reduced adverse effects in anti-angiogenic drug treatments
基于绿茶的纳米增强剂作为抗血管生成药物治疗中增强疗效并减少不良反应的佐剂
- 批准号:
23K17212 - 财政年份:2023
- 资助金额:
$ 14.75万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Effects of Tobacco Heating System on the male reproductive function and towards to the reduce of the adverse effects.
烟草加热系统对男性生殖功能的影响以及减少不利影响。
- 批准号:
22H03519 - 财政年份:2022
- 资助金额:
$ 14.75万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Mitigating the Adverse Effects of Ultrafines in Pressure Filtration of Oil Sands Tailings
减轻油砂尾矿压力过滤中超细粉的不利影响
- 批准号:
563657-2021 - 财政年份:2022
- 资助金额:
$ 14.75万 - 项目类别:
Alliance Grants
1/4-Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
1/4-破译ECT结果和不良反应的机制(DECODE)
- 批准号:
10521849 - 财政年份:2022
- 资助金额:
$ 14.75万 - 项目类别:
4/4-Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
4/4-破译ECT结果和不良反应的机制(DECODE)
- 批准号:
10671022 - 财政年份:2022
- 资助金额:
$ 14.75万 - 项目类别:
2/4 Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
2/4 ECT 结果和不良反应的破译机制(DECODE)
- 批准号:
10670918 - 财政年份:2022
- 资助金额:
$ 14.75万 - 项目类别:
Adverse Effects of Using Laser Diagnostics in High-Speed Compressible Flows
在高速可压缩流中使用激光诊断的不利影响
- 批准号:
RGPIN-2018-04753 - 财政年份:2022
- 资助金额:
$ 14.75万 - 项目类别:
Discovery Grants Program - Individual